UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1-2 Study of BMN 270 in Hemophilia A 2nd January 2017 Mark Ward Leave a comment UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1-2 Study of BMN 270 in Hemophilia A
